Category: Joint ventures/collaborations
-
A.I. to Identify Treatment Drivers for Colorectal Cancer
A study will soon get underway with artificial intelligence and simulation analyzing data from clinical trials to identify factors behind responses to a treatment for colorectal cancer.
-
Genomics-Blockchain Company Launches, Raises $4.3 Million
A new enterprise that promises to collect and protect a person’s genomic data with blockchain technology is starting up with the help of a genomics legend and $4.3 million in seed financing.
-
Genentech Gains Modular Engineered Antibodies in $5B Deal
A developer of synthetic antibodies that invoke the immune system is partnering with the biopharmaceutical company Genentech to design new therapies for blood-related and solid tumor cancers.
-
UPDATE: 23andMe Shuts Down Open API Access to Raw Data
The personal genetics company 23andMe is closing down access to its raw genomic data for independent software developers.
-
Biotechs Collaborate on More Precise Gene, Cell Cancer Therapies
Two biotechnology enterprises developing cancer treatments are pooling their efforts to develop therapies aimed at more specific targets across a range of solid tumor types.
-
Bread Wheat Genome Sequenced
An international collaboration published a complete, annotated genomic sequencing of wheat used in making bread, a widely grown staple crop and major source of nutrition worldwide.
-
Pfizer, Biotech Partner on RNA Flu Vaccine
A biotechnology company in Germany and drug maker Pfizer are developing a vaccine to prevent seasonal influenza using messenger RNA that instructs cells on production of proteins.
-
Start-Up to Tackle Neurodegenerative Diseases, Raises $31 Million
A new company is forming to develop treatments that protect against destruction of brain cells in Alzheimer’s disease and comparable nerve damage from chemotherapy.
-
Graphene Tested in Space Launch
The material graphene, studied for more than a decade on earth, is the subject of tests for its ability to withstand the rigors of space travel.
-
Allergan Licensing Crispr for Inherited Eye Disease
Drug maker Allergan is acquiring the rights from Editas Medicine to develop an application of the genome-editing technology Crispr for the inherited eye disease Leber congenital amaurosis type 10.